E. M, A., Ali, M., M. H., A., D.M., A., Soudy, A., Moussa, S. (2019). Propagation, Purification And Molecular Characterization Of RVF virus (ZH 501) Strain For Vaccine Production In Egypt. test, 4(1), 13-17. doi: 10.21608/javs.2019.62672
Abo Hatab E. M; M H Ali; Atwa M. H.; Abul Magd D.M.; Ahmed F. Soudy; Saad A. Moussa. "Propagation, Purification And Molecular Characterization Of RVF virus (ZH 501) Strain For Vaccine Production In Egypt". test, 4, 1, 2019, 13-17. doi: 10.21608/javs.2019.62672
E. M, A., Ali, M., M. H., A., D.M., A., Soudy, A., Moussa, S. (2019). 'Propagation, Purification And Molecular Characterization Of RVF virus (ZH 501) Strain For Vaccine Production In Egypt', test, 4(1), pp. 13-17. doi: 10.21608/javs.2019.62672
E. M, A., Ali, M., M. H., A., D.M., A., Soudy, A., Moussa, S. Propagation, Purification And Molecular Characterization Of RVF virus (ZH 501) Strain For Vaccine Production In Egypt. test, 2019; 4(1): 13-17. doi: 10.21608/javs.2019.62672

Propagation, Purification And Molecular Characterization Of RVF virus (ZH 501) Strain For Vaccine Production In Egypt

Journal of Applied Veterinary Sciences
Article 3, Volume 4, Issue 1, April 2019, Pages 13-17    PDF (324.64 K)
Document Type: Original Article
DOI: 10.21608/javs.2019.62672
Authors
Abo Hatab E. M1; M H Ali1; Atwa M. H.2; Abul Magd D.M.2; Ahmed F. Soudy* 2; Saad A. Moussa1
1Animal Health Research Institute, Dokki, Giza, Egypt
2Veterinary Serum and Vaccine Research Institute, Abassia, Cairo, Egypt
Abstract
Rift Valley Fever (RVF) is an endemic disease in Egypt causing disease in animals and humans since the 1977. Full molecular description of the national vaccine strain is a strategic concern to ensure the antigenic makeup of local vaccine is adequate to provide the required protective immunity for the vaccinated animal species and as a tool of final product quality control. Molecular characterization and phylogenetic analysis of Gc gene of M segment of RVF-ZH501 strain which used in local vaccine production in veterinary serum and vaccine research institute (VSVRI) were carried out in this study. RVF-ZH501 strain was propagated by passages on BHK cell line and then purified my plaque purification technique. RT-PCR for amplification of the Gc gene of M segment. Sequence analysis of the obtained PCR product carried out by MEGA7 program. The result of the study revealed that RVF strain ZH501 Gc genomic content has 99.5 % molecular identity to the strains firstly isolated in Egypt in 1977, so still suitable for vaccine production.   
Keywords
classical bursa; ELISA; inactivated vaccine; isolates of IBD; SNT
References
B.H. BIRD, T.G. KSIAZEK, S.T. NICHOL, N.J. MACLACHLAN. 2009. Rift Valley fever virus. J Am Vet Med Assoc, 234 (2009), pp. 883-893.

CAPLEN, H.; PETERS, C.J. AND BISHOP, D.H. 1985. Mutagendirected attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol; 66 (10):2271-7.

COOPER PD.1961. The plaque assay of animal viruses. Adv. Virus Res.;8:319–378.

EL-NIMR. M.M. 1980. Studies on the inactivated vaccine against Rift Valley Fever. PhD Thesis, Fac Vet Med, Assuit Univ, Egypt.

H.M. WEINGARTL, S. ZHANG, P. MARSZAL, A. MCGREEVY. BURTON. 2014. Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells. PLoS ONE, 9 (2014), p. e87385.

IKEGAMI, T, AND MAKINO, S.  .2011. The pathogenesis of Rift Valley fever Viruses, 3 (2011), pp. 493-519.

M. BOULOY, C. JANZEN, P. VIALAT, H. KHUN, J. PAVLOVIC, M. HUERRE. 2001. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus non-structural protein NSs. J Virol, 75 (2001), pp. 1371-1377.

MOHAMED A.KENAWYAYOUSRYA M. ABDEL-HAMIDBJOHN C.B EIERC .2018. Rift Valley Fever in Egypt and other African countries: Historical review, recent outbreaks and possibility of disease occurrence in Egypt. Acta Tropica. Volume 181, May 2018, Pages 40-49.

MORRILL JC, IKEGAMI T, YOSHIKAWA-IWATA N, LOKUGAMAGE N, WON S, ET AL. 2010. Rapid accumulation of virulent Rift Valley fever virus in mice from an attenuated virus carrying nucleotide substitution in the M RNA. PLos One 5: e9986.

MORRILL, J. C.; MEBUS, C. A. AND PETERS, C. J. 1997. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res.; 58(10):1110-4.

MÜLLER. R, POCH. O, DELARUE. M, BISHOP. D.H.L, BOULOY. M.  1994. Rift Valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J Gen Virol, 75 (1994), pp. 1345-1352.

OIE. 2008. Rift Valley Fever Terrestrial Manual 2.1.14. Available at http://www.oie.int/Eng/Normes/Mmanual/2008/. Accessed on 3rd June 2011.

OIE TERRESTRIAL MANUAL, . 2014. Rift Valley Fever, chapter 2.1.14. May 2014.

PEPIN, M.; BOULOY, M.; BIRD, B.H.; KEMP, A. AND PAWESKA, J. .2010. Rift Valley Fever virus (Bunyaviridae:Phlebovirus): an update on pathogenesis, molecular, epidemiology, vectors, diagnostics and prevention.Veterinary Research 41, 61.

R. DAUBNEY, J.R. HUDSON, P.C. GARNHAM .1931. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep, cattle and man from East Africa. J Pathol Bacteriol, 34 (1931), pp. 545-549.

S.R. GERRARD, and S.T. NICHOL 2007. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology, 357 (2007), pp. 124-133.

SCHMALJOHN C.S. , and NICHOL S.T.  2007. Bunyaviridae, Fields virology (5th ed.), Lippincott, Williams and Wilkins, Philadelphia, PA (2007), pp. 1741-1789.

VIALAT, P, A. BILLECOCQ, A. KOHL, M. BOULOY, 2000. The segment of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J Virol, 74 (2000), pp. 1538-1543.

VIALAT, P.; MULLER, R.; VU, T. H.; PREHAUD, C. AND BOULOY, M. 1997. Mapping of the mutations present in thegenome of the Rift Valley fever virus attenuated MP12strain and their putative role in attenuation. Virus Res.52(1):43-50.

 

Statistics
Article View: 364
PDF Download: 668